Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Immune Toleration Induction with Emicizumab in Hemophilia a Patients with Inhibitors: A Systematic Review

Prashant Raghavendran, Robert F Sidonio, Jr., Glaivy Batsuli

Blood (2024) 144 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2024-207335

Published: 2024

Journal Articles

Development of a Working Definition of Severe Von Willebrand Disease

Tung Wynn, Christopher Walsh, Jeanette Cesta, Robert F Sidonio, Jr., Stefanie Dugan, Mona Sayedul Huq

Blood (2024) 144 (Supplement 1): 5019.

https://doi.org/10.1182/blood-2024-208188

Published: 2024

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups

Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2024-194448

Published: 2024

Journal Articles

Increased Prophylactic Dosing Frequency Effectively Improve Bleeding Rates in Von Willebrand Disease Patients Who Require Higher Hemostatic Coverage - a Sub-Analysis of Data from the Wil-31 Study

Robert F Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 5498.

https://doi.org/10.1182/blood-2024-193886

Published: 2024

Journal Articles

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Robert F Sidonio, Jr., Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Carol Fedor, Priscilla Driscoll-Shempp, Michelle Kirby, Jorge Caicedo

Blood (2024) 144 (Supplement 1): 2594.

https://doi.org/10.1182/blood-2024-200261

Published: 2024

Journal Articles

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Carmen Escuriola, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2024-193874

Published: 2024

Journal Articles

Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset

Michelle Sholzberg, Angela C Weyand, Jacob S Lai, Benjamin Kim, Gary Patou, Nicole M. Engel-Nitz, Qiana Amos, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 3980.

https://doi.org/10.1182/blood-2024-206631

Published: 2024

Journal Articles

Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset

Angela C Weyand, Michelle Sholzberg, Jacob S Lai, Benjamin Kim, Adam Rosenthal, Scott M Robertson, Gary Patou, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2024-206567

Published: 2024

Journal Articles

RNAing toward a new therapy for hemophilia

Bhavya S. Doshi, Robert F. Sidonio, Jr

Blood (2024) 143 (22): 2219–2221.

https://doi.org/10.1182/blood.2024024295

Published: 2024

Journal Articles

Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module

Nicholas A. Arce, Zoe Markham-Lee, Qian Liang, Shabir Najmudin, Emily R. Legan, Gabrielle Dean, Ally J. Su, Moriah S. Wilson, Robert F. Sidonio, Pete Lollar, Jonas Emsley, Renhao Li

Blood (2024) 143 (19): 1992–2004.

https://doi.org/10.1182/blood.2023022038

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Robert F. Sidonio, Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Haduwa Momoh, Priscilla Driscoll-Shempp, Bethany Jones, Natalia Nieto, Jorge Caicedo

Blood (2023) 142 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2023-174729

Published: 2023

Journal Articles

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Kateryna V Vilchevska, Vladimir Vdovin, Margarita Timofeeva, Claudia Djambas Khayat, Adlette Inati, Robert F Sidonio, Jr.

Blood (2023) 142 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2023-180526

Published: 2023

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2023-180513

Published: 2023

Journal Articles

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease

Csongor Kiss, Zoltan Boda, Claudia Djambas Khayat, Leonid Dubey, Robert F Sidonio, Jr.

Blood (2023) 142 (Supplement 1): 3997.

https://doi.org/10.1182/blood-2023-180498

Published: 2023

Journal Articles

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Ana Boban, Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2023-180029

Published: 2023

Journal Articles

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Claudia Djambas Khayat, Robert F Sidonio, Jr., Anna Pavlova

Blood (2023) 142 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2023-180585

Published: 2023

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Shannon L Carpenter, Martin Chandler, Michael F Guerrera, Lynn Malec, Matthew Manuel, Michael Recht, Ulrike Reiss, Robert F. Sidonio, Jr., Cristina Tarango, Marijke Van den Berg, Michael Wang, Courtney D. Thornburg

Blood (2022) 140 (Supplement 1): 63–64.

https://doi.org/10.1182/blood-2022-162660

Published: 2022

Journal Articles

Assessment of Menstrual Health and Bleeding Symptoms in Adolescent Girls and Young Women with Sickle Cell Disease

Brittany Notice, Elizabeth Soffer, Yijin Xiang, Kelly Tickle, Beatrice E Gee, Robert F. Sidonio, Jr., Glaivy Batsuli

Blood (2022) 140 (Supplement 1): 5116–5118.

https://doi.org/10.1182/blood-2022-167857

Published: 2022

Journal Articles

Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0

Marquita Decker-Palmer, Susan Mathias, Hilary Colwell, Ross Crosby, Brittany Gentile, Janet Chupka, Robert F. Sidonio, Jr., Michael Recht, Amy D. Shapiro, James Zazzali

Blood (2022) 140 (Supplement 1): 11328–11329.

https://doi.org/10.1182/blood-2022-157932

Published: 2022

NARROW

Immune Toleration Induction with Emicizumab in Hemophilia a Patients with Inhibitors: A Systematic Review

Development of a Working Definition of Severe Von Willebrand Disease

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups

Increased Prophylactic Dosing Frequency Effectively Improve Bleeding Rates in Von Willebrand Disease Patients Who Require Higher Hemostatic Coverage - a Sub-Analysis of Data from the Wil-31 Study

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset

Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset

RNAing toward a new therapy for hemophilia

Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Assessment of Menstrual Health and Bleeding Symptoms in Adolescent Girls and Young Women with Sickle Cell Disease

Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only